SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharma gets USFDA’s nod for Olmesartan Medoxomil and Amlodipine Tablets

18 Jul 2017 Evaluate

Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Olmesartan Medoxomil and Amlodipine Tablets, 20 mg/5 mg, 40 mg/5 mg, 20 mg/10 mg, and 40 mg/10 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Azor Tablets, 20 mg/5 mg, 40 mg/5 mg, 20 mg/10 mg, and 40 mg/10 mg, of Daiichi Sankyo Inc.

Olmesartan Medoxomil and Amlodipine Tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. According to IMS, these tablets have an estimated market size of $ 312 million for twelve months ending December 2016. The company now has a total of 61 ANDA approvals (53 final approvals and 8 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.


Alembic Pharma Share Price

769.80 5.60 (0.73%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×